comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-03 00:00:05 - browse：8164

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Cigna, Humana reportedly in talks to merge

focus

WSS

A new crop of companies is reshaping the health data economy

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Rep. Raul Ruiz on the physician shortage and more

Cigna, Humana reportedly in talks to merge

STAT Report: Patient voices and perspectives

leisure time

comprehensive

explore

United colonoscopy coverage change 'may cost lives,' doctors say

Cigna, Humana reportedly in talks to merge

Guidelines to prevent youth baseball injuries need more muscle

Why patients can’t get everything they want on drug pricing

State Dept. review finds Biden bears some blame for Afghanistan failures

ReNAgade cuts staff seven months after raising $300 million

Apple is now the first public company to be valued at $3 trillion

The battle over 'scope creep' and who gets to be called 'doctor'

In Memoriam: Notable people who died in 2023

New Alzheimer's drugs heat up race for early detection blood tests

Wikipedia

The EPA's new lead rule: How one expert crunched the numbers

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Diagnostic tests are hitting their mathematical limits

A new crop of companies is reshaping the health data economy

In the gardens at Boston Children's Hospital, families find sanctuary

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

focus

hotspot

focus

explore